{
    "organizations": [],
    "uuid": "354f190da750cd76966b408b05f403c7b30abba7",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-exelixis-and-invenra-enter-into-co/brief-exelixis-and-invenra-enter-into-collaboration-to-develop-novel-biologics-to-treat-cancer-idUSFWN1S917W",
    "ord_in_thread": 0,
    "title": "BRIEF-Exelixis And Invenra Enter Into Collaboration To Develop Novel Biologics To Treat Cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 2 (Reuters) - Exelixis Inc:\n* EXELIXIS AND INVENRA ENTER INTO COLLABORATION TO DISCOVER AND DEVELOP NOVEL BIOLOGICS TO TREAT CANCER\n* EXELIXIS INC - COMPANIES WILL PARTNER TO ADVANCE MULTISPECIFIC ANTIBODIES IN UP TO SEVEN DISCRETE PROJECTS\n* EXELIXIS INC - EXELIXIS WILL PAY INVENRA AN UPFRONT PAYMENT OF $2.0 MILLION PLUS $2.0 MILLION AT INITIATION OF EACH DISCOVERY PROJECT Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-03T04:16:00.000+03:00",
    "crawled": "2018-05-03T12:26:19.052+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "exelixis",
        "inc",
        "exelixis",
        "invenra",
        "enter",
        "collaboration",
        "discover",
        "develop",
        "novel",
        "biologics",
        "treat",
        "cancer",
        "exelixis",
        "inc",
        "company",
        "partner",
        "advance",
        "multispecific",
        "antibody",
        "seven",
        "discrete",
        "project",
        "exelixis",
        "inc",
        "exelixis",
        "pay",
        "invenra",
        "upfront",
        "payment",
        "million",
        "plus",
        "million",
        "initiation",
        "discovery",
        "project",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}